Pharmacologic characterization of omidenepag isopropyl, a novel selective EP2 receptor agonist, as an ocular hypotensive agent

Kirihara T., Taniguchi T., Yamamura K., Iwamura R., Yoneda K., Odani-Kawabata N., Shimazaki A., Matsugi T., Shams N., Zhang J.-Z.

2018
Investigative Ophthalmology and Visual Science

View publication

Therapeutic Area

Glaucoma
Technology

Pharmacology

Affiliations

R & D Division, Santen Pharmaceutical Co., Ltd, Grand Front Osaka Tower A, Kita-Ku, Osaka, Japan; R & D Division, Santen Pharmaceutical Co., Ltd, Ikoma-shi, Nara, Japan; Corporate Research & Development, Ube Industries, Ltd, Ube, Yamaguchi, Japan; R & D Division, Santen Inc, Emeryville, CA, United States

Related Publications

Clinical outcomes of Preserflo MicroShunt implant procedure in open‑angle glaucoma patients – a 1000 eyes case-series; including subanalysis of combined cataract-glaucoma surgery and standalone surgery in pseudophakic eyes

Klabe, K.; Werth, J.P.; Kaymak, H. ; Fricke, A.

Müller glia derived EVs promote neurite recovery of an enriched population of retinal ganglion like cells derived from hESC retinal organoids after damage

Eastlake K, Lamb WDB, Tracey-White D, Shibagaki K, Khaw PT, Jayaram H, Limb GA

An Exploratory Study of Machine Learning-Based Open-Angle Glaucoma Detection Using Specific Autoantibodies

Takada N., Ishikawa M., Ninomiya T., Izumi Y., Sato K., Kunikata H., Yokoyama Y., Tsuda S., Fukuda E., Yamaguchi K., Ono C., Kirihara T., Shintani C., Hanyuda A., Goshima N., Zorumski C.F., NakazawaT.

View all Glaucoma publications